Public Offering
CEL-SCI Raises $7.2 Million in Public Offering to Advance Cancer Drug Multikine
CEL-SCI Corporation closed a $7.2 million public offering to fund continued development of its head and neck cancer treatment Multikine, highlighting the company's push to bring a novel immunotherapy to market.
Soligenix Secures $7.5 Million in Public Offering to Advance Rare Disease Pipeline Through 2026
Soligenix has closed a $7.5 million public offering that extends its financial runway through 2026, enabling continued advancement of its rare disease treatment pipeline including late-stage clinical trials and regulatory milestones.
Alpha Cognition Secures $35 Million in Oversubscribed Public Offering to Accelerate Neurodegenerative Disease Treatment Commercialization
Alpha Cognition's successful $35 million public offering will accelerate commercialization of its Alzheimer's treatment ZUNVEYL and advance development of other neurodegenerative disease therapies, addressing critical unmet medical needs.
BitMine Immersion Technologies Secures $18 Million in Public Offering to Bolster Bitcoin Investment Strategy
BitMine Immersion Technologies has successfully closed an $18 million public offering, marking a significant step in its strategy to accumulate Bitcoin through mining and capital raising, with implications for the cryptocurrency investment landscape.
BriaCell Therapeutics Raises $13.8 Million in Public Offering to Advance Cancer Immunotherapy Research
BriaCell Therapeutics has completed a public offering of 3,066,666 units, generating approximately $13.8 million to support its clinical-stage cancer immunotherapy development efforts. The funding will help the company advance its research and corporate objectives.